Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.
Artelo Biosciences, Inc. develops clinical-stage therapeutics that modulate lipid-signaling pathways, including programs tied to the endocannabinoid system and fatty acid-binding proteins. Company news commonly covers pipeline updates for ART27.13 and ART26.12, including cancer anorexia-cachexia, neuropathic pain, glaucoma, dermatologic, neurological and other inflammation-related indications.
Recurring developments include FABP5 inhibitor research, peer-reviewed publications, collaborations using biological-data analysis, preclinical and clinical program disclosures, patent activity, and externally funded studies. Artelo news also includes capital-structure actions such as private placements, common stock and warrant offerings, and Nasdaq listing-compliance matters.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.